Leproust Emily M.

About Leproust Emily M.

Emily M. Leproust, Ph.D., is a biotechnology executive best known as the co-founder, Chief Executive Officer, and Chair of the Board of Twist Bioscience Corp., a Nasdaq-listed company. Public filings show that she has served as Twist’s CEO since April 2013, as President until October 2022, and as Chair of the Board since October 2018. Her career has been central to Twist’s growth as a company focused on synthetic DNA and DNA-related products for customers across research, diagnostics, and industrial applications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1581280/000158128026000006/twst-20260105.htm?utm_source=openai)) Before founding Twist, Leproust held multiple positions at Agilent Technologies, where she worked in applications and chemistry R&D for genomics. Public biographies state that she helped develop oligolibrary synthesis technology and played a role in the SureSelect product line, which helped lower sequencing costs and supported research into numerous Mendelian diseases. That background gave her deep technical and commercial experience in next-generation genomics tools before she moved into company building. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1581280/000158128026000006/twst-20260105.htm?utm_source=openai)) Her academic credentials include an M.Sc. in Industrial Chemistry from the Lyon School of Industrial Chemistry and a Ph.D. in Organic Chemistry from the University of Houston. She is widely described as an early pioneer in high-throughput DNA synthesis and sequencing, with more than 30 peer-reviewed publications and multiple patents to her name. In 2020, BIO awarded her the Rosalind Franklin Award for Leadership, reflecting broader industry recognition of her work and leadership. ([genedx.com](https://www.genedx.com/leadership/emily-leproust?utm_source=openai)) From a governance perspective, Leproust has also served on the board of GeneDx Holdings Corp. (formerly Sema4 Holdings Corp.) since September 2020 / July 2021 according to public disclosures. That board role aligns with her expertise in genomics and life sciences and adds another public-company governance credential to her profile. Overall, her executive record combines scientific innovation, operational leadership, and board-level oversight in U.S.-listed biotechnology and healthcare companies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1581280/000158128026000006/twst-20260105.htm?utm_source=openai))